HLST 1000 Lecture Notes - Lecture 15: Pharmaceutical Industry, Health Canada
Document Summary
This chapter focuses on the background of these issues, such as how policies about them are made and the roles play by the state. It discusses the drug regulatory system such as the long relationship between pharma companies and canadian government. This occurs when there is high power in one agency such as health canada but a low degree of autonomy. The canadian government"s therapeutic products directorate enforces regulations of drug safety, quality and efficacy but doesn"t have the resources to run the clinical trials. In addition, tpd has high degree of concentrated power but carries low degree of autonomy. Pharma industry insists that the main function is to facilitate the development of new drugs and approve them as fast as possible. The policies made in regards to drugs and drug development cost hundreds of millions of dollars and since so much money is spent, companies want intellectual property rights to protect their investments in the long run.
